FS Development Corp (GMTX)

Sector:
FINANCE
Industry:
CORPORATE FINANCE
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Jason Meyenburg
Employees:
3
300 ONE KENDALL SQUARE, 3RD FLOOR, CAMBRIDGE, MA 02139
617-401-4400

Gemini is a clinical-stage precision medicine company developing novel therapeutic compounds to treat genetically defined AMD. Its lead candidate, GEM103, is a recombinant form of the Complement Factor H protein (CFH) and is designed to address both complement hyperactivity and restore retinal health. Variations in the gene that encodes CFH strongly correlate with an increased risk of developing AMD. The company is headquartered in Cambridge, MA.

View SEC Filings from GMTX instead.

View recent insider trading info

Funds Holding GMTX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding GMTX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

GEMAYEL GEORGES SEE REMARKS

  • Officer
  • Director
40,759 2021-11-15 3

PIEKOS BRIAN CHIEF FINANCIAL OFFICER

  • Officer
90,720 2021-10-18 4

GORDON CARL L

  • Director
  • 10% Owner
17,245 2021-10-04 2

LUBNER DAVID CHARLES

  • Director
17,245 2021-10-04 4

RHODES JASON P

  • Director
  • 10% Owner
17,245 2021-10-04 2

TANANBAUM JAMES B.

  • Director
  • 10% Owner
428,745 2021-10-04 2

ONG TUYEN

  • Director
17,245 2021-10-04 4

MEYENBURG JASON PATRICK PRESIDENT & CEO

  • Officer
  • Director
13,000 2021-05-14 3

STRAPPS WALTER CHIEF SCIENTIFIC OFFICER

  • Officer
9,000 2021-04-28 4

BARONE SAMUEL B. CHIEF MEDICAL OFFICER

  • Officer
255,212 2021-04-12 2

LAUDER SCOTT CHIEF TECHNOLOGY OFFICER

  • Officer
272,615 2021-02-23 3

REDMOND PRECILLIA CHIEF PEOPLE OFFICER

  • Officer
25,489 2021-02-23 3

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP VI LLC

  • Director
  • 10% Owner
5,826,224 2021-02-05 1

BELOFF GREGG CHIEF FINANCIAL OFFICER

  • Officer
0 2021-02-05 1

GEORGE JEAN

  • Director
  • 10% Owner
4,836,106 2021-02-05 1

LSV ASSOCIATES, LLC

LIGHTSTONE VENTURES, L.P.

LIGHTSTONE VENTURES (A), L.P.

LIGHTSTONE SINGAPORE, L.P.

LIGHTSTONE SINGAPORE ASSOCIATES, LLC

CARUSI MICHAEL A

PLAIN HENRY A JR

  • 10% Owner
4,836,106 2021-02-05 1

ATLAS VENTURE FUND X, L.P.

ATLAS VENTURE ASSOCIATES X, L.P.

ATLAS VENTURE ASSOCIATES X, LLC

ATLAS VENTURE OPPORTUNITY FUND I, L.P.

ATLAS VENTURE ASSOCIATES OPPORTUNITY I, L.P.

ATLAS VENTURE ASSOCIATES OPPORTUNITY I, LLC

ATLAS VENTURE FUND XII, L.P.

ATLAS VENTURE ASSOCIATES XII, L.P.

ATLAS VENTURE ASSOCIATES XII, LLC

  • 10% Owner
5,254,365 2021-02-05 1

FS DEVELOPMENT HOLDINGS, LLC

FORESITE CAPITAL FUND V, L.P.

FORESITE CAPITAL MANAGEMENT V, LLC

FORESITE CAPITAL OPPORTUNITY FUND V, L.P.

FORESITE CAPITAL OPPORTUNITY MANAGEMENT V, LLC

  • 10% Owner
  • DIRECTOR BY DEPUTIZATIONDIRECTOR BY DEPUTIZATIONDIRECTOR BY DEPUTIZATIONDIRECTOR BY DEPUTIZATIONDIRECTOR BY DEPUTIZATION
4,870,250 2021-02-05 1

UKNIS MARC CHIEF MEDICAL OFFICER

  • Officer
277,117 2021-02-05 2

FORESITE CAPITAL OPPORTUNITY FUND V, L.P.

FORESITE CAPITAL OPPORTUNITY MANAGEMENT V, LLC

  • 10% Owner
441,500 2020-10-19 0

FS DEVELOPMENT HOLDINGS, LLC

FORESITE CAPITAL FUND V, L.P.

FORESITE CAPITAL MANAGEMENT V, LLC

TANANBAUM JAMES B. PRESIDENT & CEO

  • Officer
  • Director
  • 10% Owner
441,500 2020-08-14 1

PAKIANATHAN DEEPIKA

  • Director
0 2020-08-11 0

CAREY ROBERT

  • Director
0 2020-08-11 0

FS DEVELOPMENT HOLDINGS, LLC

FORESITE CAPITAL FUND V, L.P.

FORESITE CAPITAL MANAGEMENT V, LLC

  • 10% Owner
0 2020-08-11 0

BAJAJ VIKRAM

  • Director
0 2020-08-11 0

DUBIN DANIEL

  • Director
0 2020-08-11 0

FS DEVELOPMENT HOLDINGS, LLC

  • 10% Owner
0 2020-08-11 1

RYAN DENNIS D CHIEF FINANCIAL OFFICER

  • Officer
0 2020-08-11 0

ROME MICHAEL E VICE PRESIDENT

  • Officer
  • Director
0 2020-08-11 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

GEMAYEL GEORGES - Director - Officer SEE REMARKS

2021-11-16 07:56:41 -0500 2021-11-15 A 17,245 a 17,245 direct

GEMAYEL GEORGES - Director - Officer SEE REMARKS

2021-11-16 07:56:41 -0500 2021-11-15 A 23,514 a 23,514 direct

PIEKOS BRIAN - Officer CHIEF FINANCIAL OFFICER

2021-10-20 17:49:59 -0400 2021-10-18 A 90,720 a 90,720 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
GEMINI THERAPEUTICS INC GMTX 2021-12-03 22:15:03 UTC -0.7468 0.8168 200000
GEMINI THERAPEUTICS INC GMTX 2021-12-03 21:45:03 UTC -0.7468 0.8168 200000
GEMINI THERAPEUTICS INC GMTX 2021-12-03 21:15:04 UTC -0.7468 0.8168 200000
GEMINI THERAPEUTICS INC GMTX 2021-12-03 20:45:03 UTC -0.7468 0.8168 200000
GEMINI THERAPEUTICS INC GMTX 2021-12-03 20:15:03 UTC -0.7468 0.8168 200000
GEMINI THERAPEUTICS INC GMTX 2021-12-03 19:45:03 UTC -0.7468 0.8168 200000
GEMINI THERAPEUTICS INC GMTX 2021-12-03 19:15:04 UTC -0.7468 0.8168 200000
GEMINI THERAPEUTICS INC GMTX 2021-12-03 18:45:04 UTC -0.7468 0.8168 200000
GEMINI THERAPEUTICS INC GMTX 2021-12-03 18:15:03 UTC -0.7468 0.8168 200000
GEMINI THERAPEUTICS INC GMTX 2021-12-03 17:45:03 UTC -0.7468 0.8168 200000
GEMINI THERAPEUTICS INC GMTX 2021-12-03 17:15:03 UTC -0.7468 0.8168 200000
GEMINI THERAPEUTICS INC GMTX 2021-12-03 16:45:03 UTC -0.7468 0.8168 200000
GEMINI THERAPEUTICS INC GMTX 2021-12-03 16:15:04 UTC -0.7468 0.8168 200000
GEMINI THERAPEUTICS INC GMTX 2021-12-03 15:45:03 UTC -0.7468 0.8168 200000
GEMINI THERAPEUTICS INC GMTX 2021-12-03 15:15:03 UTC -0.7468 0.8168 200000
GEMINI THERAPEUTICS INC GMTX 2021-12-03 14:45:03 UTC -0.7201 0.7901 200000
GEMINI THERAPEUTICS INC GMTX 2021-12-03 14:15:05 UTC -0.7201 0.7901 200000
GEMINI THERAPEUTICS INC GMTX 2021-12-03 13:45:03 UTC -0.7201 0.7901 200000
GEMINI THERAPEUTICS INC GMTX 2021-12-03 13:15:03 UTC -0.7201 0.7901 200000
GEMINI THERAPEUTICS INC GMTX 2021-12-03 12:45:03 UTC -0.7201 0.7901 200000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments